EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›MNKD

MNKD

MANNKIND CORP

Next earnings Aug 4, 2026 (after close) · consensus $-0.00 EPS, $111M rev

Last earnings +24.5% on 2026-05-06

Hold
$4.14
▲ +5.34%
$4.14▲ +8.95%
over 1Y
L $2.28EODHDH $6.21
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.3%
1W+6.4%
1M+16.6%
3M+81.6%
YTD-26.1%
1Y+8.9%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
D
Valuation
Overvalued
Filings
Watch
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy

Revenue grew 22.2% YoY; but thin net margin (1.7%).

Revenue (FY2025) $349M · FY2025

The read

Middling fundamentals and a rich price (~96% above fair value) leave little margin of safety — a wait-and-see.

MANNKIND CORP shows $349M in FY2025 revenue (+22.2% YoY), a 1.7% net margin.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$75.4M$99.8M$199M$286M$349M
Gross profit—————
Operating income-$47.0M-$64.1M$8.68M$72.6M$38.8M
Net income-$80.9M-$87.4M-$11.9M$27.6M$5.86M
Diluted EPS-$0.32-$0.34-$0.04$0.10$0.02
Net margin-107.3%-87.6%-6.0%9.7%1.7%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$1.56B
EV / EBITDA30.4
EV / Sales4.5
EV / FCF113.6
P / FCF93.2
PEG (trailing)—
Earnings yield0.5%
FCF yield1.1%

Quality & risk

ROIC (est.)—
Free cash flow$13.7M
Total debt$355M
Net cash-$280M
Altman Z-Score-3.96 distress
Piotroski F-Score3/8

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.5%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Other event2026-06-02
  2. 8-K Other event2026-05-28
  3. 8-K Shareholder vote2026-05-22
  4. 8-K Earnings results2026-05-06
  5. 10-Q Quarterly report2026-05-06
  6. DEF 14A Proxy statement2026-04-07
  7. 8-K Earnings results2026-02-26
  8. 10-K Annual report2026-02-26
  9. 8-K/A Amended 8-K2025-12-15

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-05-292026-06-02open ↗8-KPeriod ending 2026-05-272026-05-28open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗

Quality score

D
ValueGrowthProfitHealthMom.
ValueD
GrowthC-
ProfitabilityC
Financial healthF
Momentum—
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✓Liabilities below 2× equity
  • ✗P/E below 25

Fair value est.

$0.16

Overvalued -96% vs price

cheapfair valueexpensive

Modified Graham: EPS $0.02 × (8.5 + 1.5 × 0.0% growth) × 0.95 quality = 8.1× multiple. An estimate, not a price target.

Revenue
$349M
+22.2% YoY
Net margin
1.7%
ROE
—
P/E
207.0

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$349M+22.2%
Net income$5.86M-78.7%
Operating income$38.8M-46.5%
Diluted EPS$0.02-80.0%
Cash & equivalents$74.9M+61.6%
Total assets$792M+101.1%
Total liabilities$843M+78.4%
Stockholders' equity-$51.0M+35.3%
Op.: 11.1%L/E: -16.53x

Frequently asked

Is MANNKIND CORP (MNKD) a buy?
MNKD currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 22.2% YoY; but thin net margin (1.7%).
What is MNKD's fair value?
A Modified-Graham model based on MNKD's SEC fundamentals estimates a fair value of about $0.16. It is an estimate from reported earnings, not a price target.
Is MNKD overvalued or undervalued?
Against a Modified-Graham fair-value estimate, MNKD currently appears overvalued relative to its SEC-grounded earnings power.
What is MANNKIND CORP's quality score?
MNKD scores 48.50980392156863/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000899460, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 5:57:22 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-05-20
Consiglio Ronald J
Director
Award10.0K @ $2.95$29.5K
2026-05-20
Tross Stuart A
Chief People & Workpl Officer
Award33.9K @ $2.95$100.0K
2026-05-20
Marasco Dominic
Pres, Endocrine Business Unit
Award8.47K @ $2.95$25.0K

Earnings history

beat/miss · move
2026-05-06Miss -3233.3% est▲ +24.48%8-K ↗
2026-02-26Miss -440.1% est▼ -7.43%8-K ↗
2025-11-05Beat +205.9% est▲ +10.58%8-K ↗
2025-08-06Miss -100.0% est▼ -13.03%8-K ↗
2025-05-08—▼ -4.54%8-K ↗
2025-02-26—▼ -3.19%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1DBullish
finance.yahoo.com· 2026-06-23
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”Bullish
finance.yahoo.com· 2026-06-13
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical DataBullish
finance.yahoo.com· 2026-06-12
Jim Cramer Says He Blessed MannKind as a Speculation OnlyBullish
finance.yahoo.com· 2026-06-08
Mankind: Afreezza Data At ADA 2026 Underscores Pediatric Safety And Expands Use In Diabetes CareBullish
nasdaq.com· 2026-06-08
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) SystemsBullish
finance.yahoo.com· 2026-06-05

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score49 vs 67
Revenue growth22.2% vs 7.1%
Net margin1.7% vs 10.5%
Return on equity— vs 12.3%
P/E207.0 vs 25.5

News sentiment

EODHD · 17d
Bullish
+0.17
vs typical · 32 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.